stockrow
Saturday 7 November 2026
Export LYEL’s income statement to Excel — free account
Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024.
- Revenue
- −80.0%
- EPS
- +12.7%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
14.82
0.18
−1.20%
Follow LYEL
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
15,948.56 | 12,157.93 | 14,155.89 | 14,614.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.92) | (9.68) | (11.40) | (16.31) | |
P/B ratio |
1.24 | 1.40 | 1.60 | 2.12 | |
Price to Tangible BV |
1.24 | 1.40 | 1.60 | 2.12 | |
EV/Sales |
4,141.50 | 4,598.60 | 5,961.60 | 7,747.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.45) | (0.93) | (1.38) | (1.86) | |
EV/FCF |
(0.34) | (0.71) | (1.05) | (1.45) | |
Quick Ratio |
3.83 | 5.12 | 6.88 | 5.00 | |
Current Ratio |
4.02 | 5.36 | 7.23 | 5.28 | |
Net Debt/EBITDA |
3.77 | 4.44 | 5.93 | 1.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 0.76 | 1.59 | 0.23 | |
Capex/Depreciation |
0.00 | (0.18) | (0.06) | (31.02) | |
Research and Development Expense of Revenue |
0.00% | 988,100.00% | 1,830,200.00% | 869,983.33% | |
Selling, General and Administrative Expense of Revenue |
309,900.00% | 239,400.00% | 477,750.00% | 176,933.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
150,466.67% | 113,300.00% | 214,750.00% | 426,150.00% | |
Graham Net Nets |
0.44 | 0.41 | 0.43 | 0.32 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(128.29%) | (91.32%) | (68.79%) | (52.96%) | |
Free Cash Flow Yield |
(75.60%) | (53.27%) | (39.95%) | (36.44%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.41) | (1.45) | (1.76) | (1.89) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (2.43) | |
Free Cash Flow per Share |
(1.41) | (1.46) | (1.76) | (4.31) | |
Cash per Share |
7.25 | 8.74 | 11.61 | 14.46 | |
Shareholders Equity per Share |
7.89 | 10.01 | 12.51 | 14.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.89 | 10.01 | 12.51 | 14.52 | |
Free Cash Flow |
(34.57) | (34.17) | (38.60) | (73.73) | |
Working Capital |
139.94 | 173.67 | 230.36 | 211.53 | |
Capital Expenditures |
— | (0.25) | (0.09) | (41.47) | |
Net Current Asset Value |
105.08 | 136.20 | 190.34 | 169.09 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 62.75 | 44.50 | 6,912.50 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.30 | 3.63 | 4.60 | 4.13 | |
Average Assets |
340.91 | 348.30 | 390.21 | 415.46 | |
Average Common Equity |
260.92 | 266.37 | 305.09 | 315.51 |
Columns are period end dates · fundamentals updated 4 Nov 2026